The Collaborative Cancer Cloud combines Intel technologies and bioscience advancements to enable solutions that make it easier, faster and more affordable for developers, researchers and clinicians to determine how hundreds, even thousands of genes interact to drive disease in individual patients. The cancer cloud is designed to scale to unprecedented volumes of data and allows for secure, aggregated computation across distributed sites without loss of local control of the data, ensuring an institution’s ability to maintain proper custody of its datasets and protecting patient privacy and any institutional intellectual property that may result.
Engineers and scientists have come together to form a dynamic, new type of team that is developing novel hardware and software technologies optimized for current precision medicine analytics but engineered for longevity – with inherent flexibility to work with future computer platforms, data standards and analytics solutions. The Collaborative Cancer Cloud’s unique technical capabilities are what attracted the two research institutions to join the collaboration.
“Through Dana-Farber’s ‘Profile’ project, we have created one of the world’s largest databases of genetic abnormalities that drive cancer, with over 15,000 genetic profiles of patients' tumors, adding about 400 each month to the database,” said Barrett Rollins, M.D.,Ph.D, chief scientific officer, Dana-Farber Cancer Institute. “We are excited to be part of the Collaborative Cancer Cloud and are convinced that the innovative data sharing structure developed by Intel and our academic partners will accelerate the delivery of better treatments to our patients.”
"To understand the causes of cancer and to develop more effective methods of prevention, detection and treatment, cancer researchers need access to rich molecular and clinical data sets,” said Lincoln Stein, M.D., Ph.D., director of the Informatics and bio-computing program for the Ontario Institute for Cancer Research, and professor, department of molecular genetics at the University of Toronto. “However the information is often siloed and unmanageably large, rendering it effectively inaccessible. Projects like the Collaborative Cancer Cloud overcome the barriers to working with these data sets by allowing multiple institutions to pool their data and to provide researchers with the computer power needed to work on the data remotely. We’re very eager to begin collaborative cancer research with these other leading institutions.” Stein works in conjunction with Paul Boutros, the OICR lead for the CCC project.
OHSU Knight Cancer Institute, Dana-Farber Cancer Institute, and Ontario Institute for Cancer Research together with Intel believe that to better understand complex diseases like cancer, the medical and technology industries must collaborate to make the growing wealth of insights from analyzing public and private genetic datasets accessible for the patient’s benefit.
The expansion of this shareable cancer-treatment knowledge base promises to help advance cancer research and contribute to improved outcomes for patients around the world.
“The entire research community can benefit from insights revealed in large data cohorts,” said Brian Druker, M.D., director of the OHSU Knight Cancer Institute. “By securely sharing clinical and research data among institutions, while maintaining patient privacy, our goal is to turn a process that’s agonizing and uncertain for countless patients into a highly tailored, one-day diagnosis and treatment recommendation.“
Together with Intel Corporation, the three cancer institutions will initially focus on developing genomic pilot projects based on leading industry-standard tools, and will identify novel analytics approaches using machine learning techniques against a collective set of molecular and imaging data in order to support big data analytics in a federated, aligned environment.
“The end goal is to empower researchers and doctors to help patients receive a diagnosis based on their genome and arm clinicians with the data needed for a targeted treatment plan. By 2020, we envision this happening in 24 hours — ‘All in One Day,’” said Eric Dishman, vice president and general manager, Health and Life Sciences Group, Intel. “We are honored to bring Intel technology to the Collaborative Cancer Cloud and advance the processing, storage, networking, data security and advanced analytics necessary to push the boundaries of precision medicine and bring us closer than ever to truly making care personal.”
Long term, OHSU and Intel aim to open this federated, secure Collaborative Cancer Cloud platform to dozens of other institutions, accelerating the ability of clinicians and researchers around the world to understand the root causes of cancer and develop targeted, molecular treatments. In the future, these underlying technologies may be applied to cardiovascular diseases and neurological disorders, among others, to accelerate scientific discovery, yield new insights and inform treatment plans. A long-term goal of the collaboration is to reduce “big data” barriers and help make precision medicine widely available to patients.
About Dana-Farber Cancer Institute
Dana-Farber is dedicated to a unique, 50/50 balance between cancer research and care, and much of the Institute’s work is dedicated to translating the results of its discovery into new treatments for patients locally and around the world. Dana-Farber sits at the center of a wide range of collaborative efforts to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. Dana-Farber/Brigham and Women’s Cancer Center provides the latest in cancer care for adults; Dana-Farber/Boston Children's Cancer and Blood Disorders Center for children. The Dana-Farber/Harvard Cancer Center unites the cancer research efforts of five Harvard academic medical centers and two graduate schools, while Dana-Farber Community Cancer Care provides high quality cancer treatment in communities outside Boston’s Longwood Medical Area.
About Ontario Institute for Cancer Research
The Ontario Institute for Cancer Research (OICR) is the largest repository of cancer genomes in Canada. OICR hosts the Secretariat and Data Coordination Center (DCC) for the International Cancer Genome Consortium (ICGC) and co-hosts the Secretariat for the Global Alliance for Genomics and Health. OICR is an innovative cancer research and development institute dedicated to prevention, early detection, diagnosis and treatment of cancer. The Institute is an independent, not-for-profit corporation, supported by the Government of Ontario. OICR's research supports more than 1,700 investigators, clinician scientists, research staff and trainees located at its headquarters and in research institutes and academia across the Province of Ontario. OICR has key research efforts underway in small molecules, biologics, stem cells, imaging, genomics, informatics and bio-computing. For more information, please visit the website at www.oicr.on.ca.
About the Knight Cancer Institute
The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials. For additional information on the OHSU Knight Cancer Institute visit www.ohsu.edu/xd/health/services/cancer.
RSS